Group Life & Health Insurance v. Royal Drug Co.

Background

Eighteen owners of independent pharmacies in San Antonio sued Blue Shield of Texas and three other local pharmacies, accusing them of agreeing to fix retail drug prices and causing policyholders not to use some independent stores. The trial court sided with Blue Shield, ruling the pharmacy agreements were part of the “business of insurance,” regulated by Texas law, and therefore exempt from federal antitrust laws; the Court of Appeals reversed that ruling.

Reasoning

The Supreme Court affirmed the Court of Appeals. The majority explained that the key feature of insurance is underwriting and spreading risk across many policyholders. The Court found that Blue Shield’s Pharmacy Agreements simply set purchase prices with pharmacies so the insurer can lower its costs; they do not themselves spread or underwrite policyholder risk and are contracts with outside vendors, not agreements between insurer and insured. The Court also relied on the Act’s history and its narrow approach to antitrust exemptions, noting Congress aimed to protect traditional underwriting and intra-industry rate-making, not broad business deals with non‑insurers.

Real world impact

The ruling means provider contracts like Blue Shield’s are not automatically immune from federal antitrust scrutiny. Whether any particular agreement violates antitrust law still depends on further factual and legal review, including whether the conduct is regulated by state law or falls into the Act’s boycott exception.

Dissents or concurrances

Justice Brennan dissented, arguing service-benefit plans and necessary provider agreements were historically treated as insurance and that these pharmacy contracts closely affect rates and insurer reliability, so they should fall within the exemption.